Keyword: Christophe Weber
Takeda flagged 12 candidates it aims to launch by 2024 that together could bring in $10B in peak sales and raised its cost-saving goal to $2.3B.
To pull off the Shire acquisition, Takeda took on a huge debt load. Thanks to a series of selloffs, the company's debt-lowering initiative moved faster than expected last year.
AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.
The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.
Worries about competition to Shire's bread-and-butter hemophilia franchise were clear even before Takeda bought it. That fear has become reality.
The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.
Takeda, in its first year counting the Shire business, managed to turn up revenue growth. But the upcoming fiscal year could be a different story.
Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.
The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.
With a critical shareholder vote looming, Takeda's CFO says the company will consider selling up to $10 billion in assets to help fund its Shire buy.
